Income statement
GBP
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7M | 6M | 7M | 9M | 9M |
| Gross Profit | 3M | 3M | 3M | 5M | 6M |
| Operating Income | -3M | -2M | -1M | 111K | 698K |
| EBITDA | -2M | -2M | -707K | 750K | 1M |
| Net Income | -2M | -2M | -1M | 1M | 2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.07
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
IXICO plc (PHYOF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.07 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +13.3%, EPS growth of +55.3%, a dividend yield of 0.0%. What stands out right now is revenue +13.3%, EPS +55.3%, free cash flow +14.8% with operating margin -34.9% and ROIC -12.9%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Stock Foundry combines PHYOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHYOF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHYOF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHYOF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$9.2M
+6.3% YoY
FY Net Income
$1.5M
+46.5% YoY
Free Cash Flow
-$1.5M
-89.0% YoY
Revenue Growth
+13.3%
EPS Growth
+55.3%
Gross Margin
47.3%
Net Margin
-25.3%
Income statement
GBP
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7M | 6M | 7M | 9M | 9M |
| Gross Profit | 3M | 3M | 3M | 5M | 6M |
| Operating Income | -3M | -2M | -1M | 111K | 698K |
| EBITDA | -2M | -2M | -707K | 750K | 1M |
| Net Income | -2M | -2M | -1M | 1M | 2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
GBP
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 2M | 4M | 6M | 7M |
| Total Assets | 14M | 11M | 13M | 15M | 14M |
| Total Liabilities | 2M | 2M | 2M | 2M | 3M |
| Shareholder Equity | 12M | 9M | 11M | 12M | 11M |
| Total Debt | 179K | 314K | 387K | 516K | 597K |
| Net Debt | -3M | -1M | -4M | -5M | -6M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
614K
-57.1% YoY
Capital Expenditures
2M
+4.1% YoY
Free Cash Flow
2M
-89.0% YoY
Key ratios
Gross Margin
47.3%
Operating Margin
-34.9%
Net Margin
-25.3%
ROE
-13.7%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.